

# Prevention of the Gastrointestinal Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs

## The Role of Proton Pump Inhibitors

Gregor J.E. Brown and Neville D. Yeomans

The University of Melbourne Department of Medicine, Western Hospital, Melbourne, Victoria, Australia

### Contents

|   |     |
|---|-----|
| Abstract  | 503 |
| 1. Background   | 504 |
| 1.1 Risks of Damage and Ulceration Induced by Nonsteroidal Anti-inflammatory Drugs (NSAIDs) | 504 |
| 1.2 Rationale for Acid Suppression  | 504 |
| 2. Non-Proton Pump Inhibitor Strategies for Risk Reduction                                  | 505 |
| 2.1 NSAID Selection   | 505 |
| 2.2 Cytoprotection  | 505 |
| 2.3 Histamine H <sub>2</sub> Antagonists  | 506 |
| 3. Clinical Studies of Proton Pump Inhibitors for Prophylaxis of NSAID Injury               | 506 |
| 3.1 Short Term Studies (Up To 1 Month)  | 506 |
| 3.2 Longer Term Studies (More Than 1 Month)   | 508 |
| 3.2.1 Proton Pump Inhibitors Versus Placebo   | 508 |
| 3.2.2 Proton Pump Inhibitor Versus H <sub>2</sub> Antagonist                                | 508 |
| 3.2.3 Proton Pump Inhibitor Versus Misoprostol  | 509 |
| 3.3 Future Research Needs   | 510 |
| 4. Conclusions  | 510 |

### Abstract

The associations between nonsteroidal anti-inflammatory drugs (NSAIDs) and the presence and complications of gastroduodenal erosions and ulcers are well established. Evidence that acid aggravates NSAID-induced injury provides a rationale for minimising such damage by acid suppression. Other strategies discussed include avoidance of NSAIDs or minimising their dosage, selecting NSAIDs known to cause less damage, and co-prescription of various agents.

Cytoprotection with misoprostol, a prostaglandin analogue, has been shown to be effective in reducing NSAID-related peptic ulcers and their complications. Unfortunately, adverse effects may limit compliance in some patients. Histamine H<sub>2</sub> antagonists have only limited efficacy in the prevention of NSAID-induced ulcers in humans, particularly in the stomach, except at higher than standard dosages. This may relate to their relatively modest effect in elevating gastric pH, especially in comparison with proton pump inhibitors.

Several studies now confirm the efficacy of proton pump inhibitors in the short and longer term prevention of NSAID-induced upper gastrointestinal injury. Pla-

cebo-controlled studies suggest reductions of over 70% in gastric and duodenal ulcer rates over 3 to 6 months. The recent ASTRONAUT (Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment) study documented the greater prophylactic efficacy of omeprazole over ranitidine at standard dosages for 6 months. The OMNIUM (Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management) study showed omeprazole to be slightly more effective overall than misoprostol in preventing the upper gastrointestinal adverse effects of NSAIDs, with both substantially more effective than placebo, although misoprostol was somewhat less well tolerated.

Although substantial reductions in NSAID ulceration are now achievable when co-therapy with a proton pump inhibitor is given, a few patients will still develop ulcers and their complications. Hence the judicious use of NSAIDs in the first instance cannot be overemphasised.

The aims of this review are to briefly define the problem of ulceration of the upper gut induced by nonsteroidal anti-inflammatory drugs (NSAIDs), then discuss the rationale for the hypothesis that markedly reducing gastric acidity should reduce this ulcer risk. The remainder of the review addresses the evidence for clinical benefit when a proton pump inhibitor and some other agents are co-prescribed with NSAIDs. The literature was searched using Medline supplemented with scanning of abstracts of recent major scientific meetings.

## 1. Background

### 1.1 Risks of Damage and Ulceration Induced by Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

The toxic effects of NSAIDs on the upper gastrointestinal tract are a frequent cause of morbidity and even mortality.<sup>[1]</sup> Awareness of peptic ulcer as a complication of anti-inflammatory dosages of NSAIDs is high and, probably because of this, NSAID usage has diminished recently in some Western countries.<sup>[2]</sup> There is also hope that the newer NSAIDs that are selective inhibitors of cyclo-oxygenase (COX)-2 (rather than of the constitutive isoenzyme COX-1) will cause less gastroduodenal ulceration in the future. On the other hand, prescribing of low dosage (75 to 300 mg/day) aspirin (acetylsalicylic acid) for the prevention of

stroke and myocardial infarction is increasing, and this will produce an increasing burden of ulceration as an adverse event.

With the current generation of NSAIDs, the great majority of patients develop some erosions in the stomach after each dose,<sup>[3]</sup> and about 15 to 25% of patients who have been taking NSAIDs regularly will be found to have a discrete ulcer if they are examined with gastroscopy at any point in time.<sup>[3,4]</sup> Most ulcers found in this way are asymptomatic and quite small.<sup>[3]</sup> They presumably heal and reappear a number of times before reaching a threshold for diagnosis in normal practice.

The most important complications of NSAID-induced ulceration of the stomach or duodenum are haemorrhage and perforation. Case-control studies have shown that NSAIDs increase the risk of these complications by about 3 to 10 times,<sup>[4]</sup> and for some particular NSAIDs the risk is higher still. Even low dosage aspirin increases the chance of ulcer haemorrhage or perforation by 2 to 4 times.<sup>[5]</sup>

### 1.2 Rationale for Acid Suppression

Luminal acid appears to contribute to NSAID injury in the stomach in 2 ways. First, most NSAIDs are weak acids with pKa values in the range 3.5 to 6. This means that they are mostly non-ionised at the usual pH of the stomach and the duodenal bulb. As a consequence, they are usually lipid soluble and can diffuse into the surface cells fairly readily. This increase in gastric absorption at

high pH is well documented with aspirin.<sup>[6,7]</sup> Having gained entry to the surface cells, aspirin becomes trapped at the higher intracellular pH and causes local toxicity. There is, however, much less evidence that this local effect is important with other NSAIDs.<sup>[8]</sup>

Secondly, acid (and possibly pepsin) appears to produce a 'second wave' of injury, deepening some of the superficial erosions that are very widespread soon after administration of an NSAID. Much of the superficial injury repairs within an hour or two, but here and there the damaged surface seems not to repair in time before the acid in the lumen causes further deeper destruction of tissue.<sup>[9]</sup> These focal, deeper, areas are the macroscopic erosions seen endoscopically in most patients who are taking NSAIDs. In rats, vagotomy reduces this deeper damage without altering the initial superficial injury by NSAIDs.<sup>[10,11]</sup> More recent data from Elliott et al.<sup>[12]</sup> show that gastric mucosal injury in the rat is much reduced when the luminal pH is elevated above a threshold of about 4.0 (fig. 1). This pH is rarely achieved for long after H<sub>2</sub> antagonists, but can be readily achieved for at least half of each 24-hour period during administration of proton pump inhibitors at standard dosages.<sup>[13,14]</sup>

## 2. Non-Proton Pump Inhibitor Strategies for Risk Reduction

### 2.1 NSAID Selection

Against this background of ulcer risk, there are a number of clinical and pharmacological strategies that can be employed to reduce it. The first and most obvious is to avoid NSAIDs when they are not necessary. Secondly, when NSAIDs do need to be used, there is now good evidence that the risk of ulcer complications is dosage dependent,<sup>[15]</sup> so the NSAID should be used at the lowest effective dosage. A recent meta-analysis has confirmed that some NSAIDs are more damaging than others.<sup>[15]</sup> For example, the short-acting NSAIDs ibuprofen and diclofenac (at standard dosage) have usually been found to have relative risks of the order of 3 to 5 for ulcer bleeding, whereas some of the long-

acting drugs recommended for once-daily administration have relative risks of 10 or higher. Thus the clinician should consider choosing an agent from the less damaging end of the spectrum unless there is a particular need for one of the more potent agents or formulations. The new highly selective COX-2 inhibitors, already marketed in some countries, offer a further choice, particularly in patients at high risk of NSAID ulceration.

### 2.2 Cytoprotection

Coadministering a prostaglandin analogue reduces the gastric and duodenal damage caused by NSAIDs. This approach was developed knowing that prostaglandins are defensive factors in the normal gastric mucosa and that NSAIDs exert their damage, at least in part, by inhibiting the production of these mucosal prostaglandins. In short term studies, prostaglandins markedly reduce the number of erosions in the stomach during NSAID administration.<sup>[16-18]</sup> In longer term studies (3 to 12 months), misoprostol – an analogue of prostaglandin E<sub>1</sub> – has been shown to reduce the incidence of gastric and duodenal ulcers by about 60 to 70%,<sup>[3,19]</sup> although higher protection rates have also been reported.<sup>[20]</sup> One large study also showed an approximate halving in the number of episodes of ulcer bleeding over a 6-month period.<sup>[21]</sup>

Thus, cytoprotection with a coadministered prostaglandin is an effective strategy for reducing




Fig. 1. Effect of gastric luminal pH on the gastric damage (% of mucosa with macroscopic haemorrhagic lesions) produced by indomethacin in rats. Injury was markedly reduced when the pH of the lumen was buffered to higher than 4 (after Elliott et al.,<sup>[12]</sup> with permission).

NSAID injury and its complications. The protection is dosage dependent, but so are the adverse effects of diarrhoea and abdominal cramps, which occur in about 10% of patients.

### 2.3 Histamine H<sub>2</sub> Antagonists

Histamine H<sub>2</sub> antagonists, at least at standard dosages, have only limited efficacy for preventing NSAID-induced ulcers in humans. Two well-conducted controlled trials showed that ranitidine 150mg twice daily gave substantial protection against the development of duodenal ulcers during NSAID administration.<sup>[22,23]</sup> Unfortunately, there was no significant protection against gastric ulcers in either study, and these are a greater problem than duodenal ulcer in NSAID users. Similarly, in another large survey of patients with arthritis, the use of cimetidine produced no reduction in the incidence of ulcer bleeding.<sup>[24]</sup>

More marked acid suppression with larger doses of H<sub>2</sub> antagonists may give better results. A recent trial by Taha et al.<sup>[25]</sup> showed a 60% reduction in gastric ulceration, and an 85% reduction in duodenal ulcers, during 6 months treatment with famotidine 40mg twice daily.

Even at these larger dosages, H<sub>2</sub> antagonists have a fairly modest effect in elevating intragastric pH. For instance, in patients taking a standard dosage of ranitidine, median pH in the stomach over a 24-hour period is rarely greater than 3.<sup>[14]</sup> In contrast, median intragastric pH in patients taking standard dosages of proton pump inhibitors is usually at least 1 unit higher, of the order of 4 to 5.<sup>[13]</sup> These are the pH values that we had previously shown need to be reached if the acid component of NSAID gastric injury is to be reduced.<sup>[12]</sup> The next section reviews the data now available about the use of proton pump inhibitors for preventing NSAID injury.

### 3. Clinical Studies of Proton Pump Inhibitors for Prophylaxis of NSAID Injury

Given the limitations of standard preventive measures, it is not surprising that attention has been

focused on proton pump inhibitors as an effective yet tolerable means of protecting the stomach from the important adverse effect of NSAIDs – peptic ulceration.

#### 3.1 Short Term Studies (Up To 1 Month)

Whether or not proton pump inhibitors protect against acute NSAID damage in humans has been examined in a number of short term trials. In most instances, the proton pump inhibitor used has been omeprazole.

Table I summarises the findings from 8 controlled, randomised, double-blind trials since 1988. The study by Bianchi Porro et al.<sup>[26]</sup> recruited patients with arthritis, who were treated with omeprazole or placebo concurrently with an NSAID for 3 weeks. This was the largest of the short term studies. All the others used healthy volunteers given an NSAID (mostly aspirin) as a single dose or for up to 2 weeks. In those studies where the NSAID was given for 5 days or less, the proton pump inhibitor or comparator drug was started a few days before the NSAID. It takes several days from the start of treatment before steady state plasma concentrations and acid suppression are reached with proton pump inhibitors,<sup>[13]</sup> so this design ensured that acid suppression was well established when the NSAID was given.

All studies demonstrated protection against NSAID gastric damage when co-therapy was given with either omeprazole or lansoprazole.

Daneshmend et al.<sup>[27]</sup> assessed gastric damage by using a gastric lavage technique to measure gastric micro-bleeding after aspirin. Blood loss was reduced about 80% when omeprazole 20 or 80 mg/day was given for a week, then aspirin 900mg administered daily on the last 2 days. The gain in protection by increasing the omeprazole dosage was small, although the study was not powered to examine the effect of dosage. However, they found a significant negative correlation between the volume of micro-bleeding and the intragastric pH achieved.

All the other studies measured gastric damage endoscopically. Usually only erosions are found

during such short term studies, and these were quantified on an ordinal scale in each report. Table I shows the percentage reduction in the proportion of patients with numerous erosions in the active treatment arms compared with placebo. The cut-off categories are arbitrary and vary somewhat between studies, but 'protected' patients generally had less than 10 erosions in gastric mucosa. Protection against erosions, defined in this way, was seen in 79 to 100% of patients treated with omeprazole 20 to 40 mg/day. A similar protection was seen in the study by Bigard<sup>[28]</sup> using omeprazole 60 mg/day, and in the small study with lansoprazole 30 mg/day.<sup>[29]</sup> Protection may be somewhat less when lansoprazole 15 mg/day is used.<sup>[30]</sup> Two studies included arms treated with ranitidine

300 mg/day, which did not confer significant protection.<sup>[30,31]</sup>

It is uncommon for ulcers to develop during such short term administration of NSAIDs. However, a few acute ulcers were seen in the studies by Scheiman et al.<sup>[32]</sup> and Bianchi Porro et al.<sup>[26]</sup> Omeprazole 40 or 20 mg/day reduced this incidence by 80 to 100% (table I), although the numbers were small and significance was reached only in the larger study.<sup>[26]</sup>

Duodenal ulcers also appeared in a few patients. In the Scheiman et al.<sup>[32]</sup> study, none occurred in the omeprazole group but 15% developed them while taking placebo plus aspirin ( $p < 0.01$ ). Only 2 duodenal ulcers developed in the Bianchi Porro et al.<sup>[26]</sup> study, 1 in each group.

**Table I.** Blinded controlled studies of effects of co-treatment with proton pump inhibitors on gastric damage during short term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs)

| Reference                            | NSAID (daily dosage)                  | Duration of NSAID use | No. of patients | Co-treatment (daily dosage) | Reduction in gastric damage <sup>a</sup> | p-Value     |
|--------------------------------------|---------------------------------------|-----------------------|-----------------|-----------------------------|--|-------------|
| Scheiman et al. <sup>[32]</sup>      | Aspirin (acetylsalicylic acid) [2.6g] | 14 days               | 20              | Placebo                     |  |             |
|                                      |                                       |                       |                 | Omeprazole (40mg)           | 79% (erosions)<br>80% (ulcers)           | <0.01<br>NS |
| Bigard <sup>[28]</sup>               | Aspirin (600mg)                       | 1 day <sup>b</sup>    | 20              | Placebo                     |  |             |
|                                      |                                       |                       |                 | Omeprazole (60mg)           | 85% (erosions)                           | <0.001      |
| Bianchi Porro et al. <sup>[26]</sup> | Several                               | 21 days               | 114             | Placebo                     |  |             |
|                                      |                                       |                       |                 | Omeprazole (20mg)           | 100% (ulcers)                            | <0.01       |
| Oddsson et al. <sup>[31]</sup>       | Naproxen (1g)                         | 5 days <sup>b</sup>   | 15              | Placebo                     |  |             |
|                                      |                                       |                       |                 | Ranitidine (300mg)          | 60%                                      | NS          |
|                                      |                                       |                       |                 | Omeprazole (40mg)           | 100%                                     | <0.05       |
| Daneshmend et al. <sup>[27]</sup>    | Aspirin (900mg)                       | 2 days <sup>b</sup>   | 16              | Placebo                     |  |             |
|                                      |                                       |                       |                 | Omeprazole (20mg)           | 79% (blood loss)                         | <0.01       |
|                                      |                                       |                       |                 | Omeprazole (80mg)           | 85% (blood loss)                         | <0.01       |
| Simon et al. <sup>[33]</sup>         | Aspirin (300mg)                       | 14 days               | 36              | Placebo                     |  |             |
|                                      |                                       |                       |                 | Omeprazole (20mg)           | 77% (erosions)                           | <0.001      |
|                                      |                                       |                       |                 | Omeprazole (40mg)           | 85% (erosions)                           | <0.001      |
| Müller et al. <sup>[30]</sup>        | Aspirin (300mg)                       | 14 days               | 30              | Placebo                     |  |             |
|                                      |                                       |                       |                 | Ranitidine (300mg)          | 43% (erosions)                           | NS          |
|                                      |                                       |                       |                 | Lansoprazole (15mg)         | 64% (erosions)                           | <0.05       |
| Bergmann et al. <sup>[29]</sup>      | Aspirin (1g)                          | 1 day <sup>b</sup>    | 12              | Placebo                     |  |             |
|                                      |                                       |                       |                 | Lansoprazole (30mg)         | 70% (mean erosion score)                 | <0.005      |
|                                      |                                       |                       |                 |                             | 100% (erosion score >2)                  | <0.05       |

a Erosions were usually quantified on scales of 0 to 4; percentage reductions generally calculated here as reduction in patients with grade 3 or 4 damage.

b Co-treatment started 2 to 6 days prior to NSAID treatment.

NS = not significant.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.